Skip to contentT
Tenax Therapeutics, Inc.
T
TENXTenax Therapeutics, Inc. Q3 2016 · 10-Q
Revenue—
Net Income$4.27M$4.27MN/M vs Q3 2015 EPS Diluted-$0.15-$0.15N/M vs Q3 2015 Operating Income$4,500,566N/M Operating Cash Flowderived-$4,280,872N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
Free Cash Flowderived-$4,280,872N/M ended Sep 30, 2016 · filed Nov 9, 2016 · 40 d after period end